vTv Therapeutics (VTVT) Expected to Post Quarterly Sales of $3.14 Million

Wall Street analysts expect vTv Therapeutics (NASDAQ:VTVT) to report $3.14 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for vTv Therapeutics’ earnings, with the lowest sales estimate coming in at $100,000.00 and the highest estimate coming in at $8.00 million. vTv Therapeutics posted sales of $30,000.00 in the same quarter last year, which would indicate a positive year-over-year growth rate of 10,366.7%. The company is scheduled to announce its next quarterly earnings report on Wednesday, May 2nd.

According to Zacks, analysts expect that vTv Therapeutics will report full-year sales of $10.88 million for the current year, with estimates ranging from $200,000.00 to $30.00 million. For the next financial year, analysts anticipate that the company will post sales of $13.40 million per share, with estimates ranging from $200,000.00 to $30.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that cover vTv Therapeutics.

vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.03). The business had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.10 million.

A number of analysts have weighed in on VTVT shares. Seaport Global Securities started coverage on shares of vTv Therapeutics in a report on Thursday, March 29th. They set a “buy” rating and a $14.00 price objective on the stock. Roth Capital started coverage on shares of vTv Therapeutics in a report on Thursday, March 8th. They set a “buy” rating and a $17.00 price objective on the stock. Zacks Investment Research cut shares of vTv Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 3rd. Northland Securities started coverage on shares of vTv Therapeutics in a report on Thursday, February 8th. They set an “outperform” rating and a $28.00 price objective on the stock. Finally, Stifel Nicolaus cut shares of vTv Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, April 10th. Seven analysts have rated the stock with a hold rating and two have given a buy rating to the company. vTv Therapeutics presently has a consensus rating of “Hold” and an average price target of $13.69.

VTVT stock traded down $0.02 during midday trading on Friday, reaching $2.09. 3,407,735 shares of the company were exchanged, compared to its average volume of 3,335,958. The company has a current ratio of 0.76, a quick ratio of 0.76 and a debt-to-equity ratio of -0.10. vTv Therapeutics has a 1-year low of $0.65 and a 1-year high of $8.40. The stock has a market cap of $69.23, a P/E ratio of -1.25 and a beta of 1.74.

Several institutional investors have recently made changes to their positions in the company. State Street Corp increased its holdings in shares of vTv Therapeutics by 2.1% in the 2nd quarter. State Street Corp now owns 98,016 shares of the biotechnology company’s stock valued at $486,000 after acquiring an additional 1,976 shares during the period. Creative Planning acquired a new position in shares of vTv Therapeutics in the 4th quarter valued at $114,000. Millennium Management LLC acquired a new position in shares of vTv Therapeutics in the 4th quarter valued at $377,000. JPMorgan Chase & Co. acquired a new position in shares of vTv Therapeutics in the 3rd quarter valued at $481,000. Finally, Royce & Associates LP acquired a new position in shares of vTv Therapeutics in the 4th quarter valued at $1,352,000. 11.20% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3377923/vtv-therapeutics-vtvt-expected-to-post-quarterly-sales-of-3-14-million.html.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease.

Get a free copy of the Zacks research report on vTv Therapeutics (VTVT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Littelfuse, Inc.  Receives $217.00 Consensus Price Target from Analysts
Littelfuse, Inc. Receives $217.00 Consensus Price Target from Analysts
Orix  Stake Increased by M&T Bank Corp
Orix Stake Increased by M&T Bank Corp
12,910 Shares in Synaptics, Incorporated  Purchased by M&T Bank Corp
12,910 Shares in Synaptics, Incorporated Purchased by M&T Bank Corp
M&T Bank Corp Has $617,000 Holdings in WellCare
M&T Bank Corp Has $617,000 Holdings in WellCare
Reliance Steel & Aluminum Co  Director Mark V. Kaminski Sells 8,200 Shares
Reliance Steel & Aluminum Co Director Mark V. Kaminski Sells 8,200 Shares
Copico  Hits 24 Hour Trading Volume of $1,269.00
Copico Hits 24 Hour Trading Volume of $1,269.00


© 2006-2018 Ticker Report. Google+.